FOXO4-DRI (10 mg Vial) Dosage Protocol
FOXO4-DRI is a modified D-retro-inverso peptide designed to disrupt the interaction between FOXO4 and p53 in senescent cells. By blocking this survival pathway, it is studied as a potential senolytic agent — capable of selectively inducing apoptosis in senescent cells while leaving healthy cells intact.
âš¡ Quickstart Highlights
Dosing & Reconstitution Guide
Route: Subcutaneous or IP (animal studies) | Frequency: Intermittent — typically 3 days on, then off
| Protocol | Dose | Days On | Frequency | Notes |
|---|---|---|---|---|
| Conservative | 1–2 mg/injection | 3 consecutive days | Monthly | Low-dose senolytic pulse |
| Moderate | 3 mg/injection | 3 consecutive days | Every 6–8 weeks | Common research range |
| High (animal-derived) | 5 mg/injection | 3 consecutive days | Quarterly | Derived from mouse model dosing |
Reconstitution Steps
- Draw 1.0 mL bacteriostatic water → 10 mg/mL concentration.
- Inject slowly down the vial wall.
- Gently swirl until dissolved.
- Refrigerate at 2–8°C; use within the active research cycle.
Supplies Planning
| Item | 3-Day Cycle (3 mg/day) | Quarterly Protocol |
|---|---|---|
| FOXO4-DRI vials (10 mg each) | 1 vial | 4 vials/year |
| Insulin syringes (U-100) | 3 | 12 |
| Bacteriostatic water (10 mL) | 1 × 10 mL | 1 × 10 mL |
| Alcohol swabs | shared | shared |
Mechanism of Action
FOXO4-DRI is a D-retro-inverso (DRI) peptide — a modified version of a sequence derived from the FOXO4 transcription factor. DRI modifications (using D-amino acids and reversed sequence) confer proteolytic stability, allowing the peptide to remain active longer in vivo.
The mechanistic hypothesis: in senescent cells, FOXO4 interacts with and stabilizes p53 in the nucleus, preventing apoptosis and allowing senescent cells to persist and accumulate. FOXO4-DRI competitively disrupts this FOXO4-p53 interaction, enabling p53 to trigger apoptosis specifically in senescent cells — which depend on this pathway more than healthy cells do.
The landmark 2017 van Deursen lab paper demonstrated that FOXO4-DRI selectively cleared p21+ senescent cells in fast-aging XFE progeroid mice, restoring fitness, fur density, and kidney function. The fundamental question of whether this translates to normal aging in humans has not yet been answered in clinical trials.
Research Findings & Safety Profile
- 2017 Nature Medicine paper: FOXO4-DRI cleared senescent cells in progeroid mouse models, restoring physical fitness and fur density.
- Selective for senescent cells over healthy cells in vitro — mechanism explained by differential FOXO4-p53 dependency.
- No published human clinical trials as of 2025; all human dosing is extrapolated from animal data.
- FOXO4-DRI is one of the most experimental peptides in current research — interpret all data with appropriate caution.
- Possible risks: unknown human safety profile, potential for unintended apoptosis in healthy cells at high doses.
- Research field of senolytics is rapidly evolving; navitoclax, dasatinib+quercetin are comparator compounds in the same space.
Storage
| State | Temperature | Duration | Notes |
|---|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months | Dry, dark conditions |
| Reconstituted | 2–8°C (35–46°F) | Use within current cycle | Prepare fresh; avoid prolonged storage |